Market capitalization | $380.37m |
Enterprise Value | $246.09m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 307.61 |
P/S ratio (TTM) P/S ratio | 475.46 |
P/B ratio (TTM) P/B ratio | 2.01 |
Revenue (TTM) Revenue | $800.00k |
EBIT (operating result TTM) EBIT | $-212.79m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
13 Analysts have issued a Prime Medicine forecast:
13 Analysts have issued a Prime Medicine forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.80 0.80 |
-
|
|
Gross Profit | -4.86 -4.86 |
71%
71%
|
|
EBITDA | -207 -207 |
30%
30%
|
EBIT (Operating Income) EBIT | -213 -213 |
21%
21%
|
Net Profit | -219 -219 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Keith Gottesdiener |
Employees | 234 |
Founded | 2019 |
Website | www.primemedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.